Literature DB >> 14647428

Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.

Kohji Nagano1, John R Masters, Akunna Akpan, Alice Yang, Steve Corless, Chris Wood, Claire Hastie, Marketa Zvelebil, Rainer Cramer, Soren Naaby-Hansen.   

Abstract

Protein expression and de novo synthesis in normal and prostate cancer cell lines derived from the same patient were compared by proteomic analysis, and the effects of INFalpha and INFgamma (INF=interferon) determined. The expressions of several INF-inducible proteins, including MxA, Nmi, PA28a and IFP53, were downregulated in the cancer cells. INFgamma induced a more than twofold increase or decrease in the synthesis rates of almost twice as many proteins in the cancer cell line. The positive regulator of INF-induced transcription ISGF3gamma was upregulated in the cancer cells and inversely regulated by INFalpha and INFgamma in the normal and cancer cells. Moreover, ISGF3gamma's induction by INFgamma in the cancer cells was more enhanced by simultaneous stimulation with EGF, than its induction in the normal cells. In all, 31 differentially regulated proteins were identified by mass spectrometry analysis, several of which are involved in chaperone-assisted protein folding in the endoplasmic reticulum (ER) or in regulated protein degradation. Our results suggest that the exclusion of proteins by the ER quality control system, crosstalk between the EGF- and INF-induced signalling pathways and the regulation of INF-inducible genes are all altered in the prostate cancer cells. The combination of upregulated activity in the growth-promoting PI3K/Akt pathway, suppression of Nmi and overexpression of hnRNP-K and c-myc proteins may explain why the prostate cancer cells were found to be more resistant to the growth inhibitory effects of INFgamma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647428     DOI: 10.1038/sj.onc.1207297

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  PDGF regulates the actin cytoskeleton through hnRNP-K-mediated activation of the ubiquitin E3-ligase MIR.

Authors:  Kohji Nagano; Beat C Bornhauser; Gayathri Warnasuriya; Alan Entwistle; Rainer Cramer; Dan Lindholm; Soren Naaby-Hansen
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

2.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.

Authors:  Amosy E M'Koma; David L Blum; Jeremy L Norris; Tatsuki Koyama; Dean Billheimer; Saundra Motley; Mayshan Ghiassi; Nika Ferdowsi; Indrani Bhowmick; Sam S Chang; Jay H Fowke; Richard M Caprioli; Neil A Bhowmick
Journal:  Biochem Biophys Res Commun       Date:  2006-12-22       Impact factor: 3.575

Review 4.  Molecular pathology of prostate cancer.

Authors:  C Hughes; A Murphy; C Martin; O Sheils; J O'Leary
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma.

Authors:  Fushi Wen; Alex Shen; Reneé Shanas; Achyut Bhattacharyya; Fangru Lian; Galen Hostetter; Jiaqi Shi
Journal:  Ann Surg Oncol       Date:  2010-05-25       Impact factor: 5.344

6.  Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.

Authors:  J Frederic Mushinski; Phuongmai Nguyen; Lisa M Stevens; Chand Khanna; Sunmin Lee; Eun Joo Chung; Min-Jung Lee; Yeong Sang Kim; W Marston Linehan; Michel A Horisberger; Jane B Trepel
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

7.  Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Authors:  Renyuan Zhou; Reneé Shanas; Mark A Nelson; Achyut Bhattacharyya; Jiaqi Shi
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

8.  Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.

Authors:  Maryam Moussavi; Howard Tearle; Ladan Fazli; John C Bell; William Jia; Paul S Rennie
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

9.  Functional proteomic analysis of long-term growth factor stimulation and receptor tyrosine kinase coactivation in Swiss 3T3 fibroblasts.

Authors:  Kohji Nagano; Akunna Akpan; Gayathri Warnasuriya; Steven Corless; Nick Totty; Alice Yang; Robert Stein; Marketa Zvelebil; Allan Stensballe; Al Burlingame; Michael Waterfield; Rainer Cramer; John F Timms; Søren Naaby-Hansen
Journal:  Mol Cell Proteomics       Date:  2012-09-06       Impact factor: 5.911

10.  Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.

Authors:  P Barboro; E Repaci; A Rubagotti; S Salvi; S Boccardo; B Spina; M Truini; C Introini; P Puppo; N Ferrari; G Carmignani; F Boccardo; C Balbi
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.